

G008
Antimony Compounds

Results of Testing

Chemical Name	CAS No.	Study Code/Type	Protocol/Guideline	Species	Exposure	Dose/Concentration	No. per Group	Results	Reference
Antimony trioxide	1309-64-4	EFTSPT Soil mobility	Non-TSCA Protocol/Guideline (docket OPTS- 42021A)	Not applicable	sand, clay, sandy and silt loams, thin layer chromatography (TLC) plates, 24 hr	100 µL	Not applicable	There was no significant evidence of mobility in any of the soil types for antimony.	52 FR 2152; 1/20/87 OTS0511117
Antimony trioxide	1309-64-4	EFTSPT Sediment adsorption	Non-TSCA Protocol/Guideline (docket OPTS- 42021A)	Not applicable	6 applications of a spike to 32 TLC plates for a total of 192 spikes	100 µL	Not applicable	Under the experimental conditions used in this study, no systematic or even significant evidence for widespread mobility was detected in any of the soil types examined (clay, sandy-loam, silt-loam, or sand).	51 FR 27598; 8/1/86 OTS0511117
Antimony trioxide	1309-64-4	HESTOX Subchronic study	Non-TSCA Protocol/Guideline (docket OPTS- 42021A)	rats	inhalation, 6 hr/d; 5d/wk; 13 wk, 27 wk recovery period	0.2, 1.0, 5.0, 25.0 mg/m ³ (nominal)	50 male; 50 female	The 2 highest dose levels produced a decrease in mean body weights (both males and females), and aspartate aminotransferase values (males) compared to the controls. Increases in the incidence of corneal irregularities (with or without opacity) were exhibited by treated males and females and controls. Increases in lung discoloration, granulomatous inflammation or granulomas in the lungs, and number of pulmonary alveolar or intra-alveolar macrophages. There were no significant differences in either the treated or control groups in mortality, or hematology values.	51 FR 6468; 2/24/86 OTS0511116